What are investors saying about ImmunityBio Inc. (IBRX) stock?
- The potential expansion of ImmunityBio's sepsis trial is a key consideration, with the commenter speculating that starting a new trial would be unnecessary if the current one is progressing well.
- A 50-60% success rate in the trial is considered a key measurement for success, with the commenter emphasizing the importance of a simple and clear outcome.
- The complexity of sepsis as a disease is highlighted, with the commenter noting that a clear and simple read on who benefits from the treatment would be more effective in gaining traction than a large and messy dataset.
| Attention | 30-day average attention | Change | |
|---|---|---|---|
| IBRX | |||
| IBRX | 0.24% | 0.23% | +0.01 pts |
Is IBRX stock sentiment bullish or bearish?
| Bullish | Bearish | ||
|---|---|---|---|
| IBRX | |||
| IBRX | 85% | 15% | |
| IBRX, 30-day average | |||
| IBRX, 30-day average | 77% | 23% | |
| Healthcare sector | |||
| Healthcare sector | 61% | 39% | |
Which topics are investors discussing about IBRX stock?
We train models to sort every post about ImmunityBio Inc. into topics, then summarize what each group is saying. Each bar is the share of the engagement on IBRX posts that went to that topic.
| Share of engagement | 30-day average share | ||
|---|---|---|---|
| Technical Analysis chart patterns and price levels | |||
| Technical Analysis chart patterns and price levels | 2% | 3% | |
What does technical analysis say about IBRX stock?
- The stock price of ImmunityBio, Inc. ($IBRX) has fallen 50% from its 52-week high, yet is still up 300% from its low, and some investors are optimistic about its future.
- The daily chart for $IBRX shows a persistent downtrend, and some analysts believe that the price will stabilize and start to rise.
What is the latest news on IBRX stock?
- IBRX CEO Reveals Fresh Anktiva Data After Bladder Cancer Trial Win — Says FDA Filing Is Just Weeks AwayYahoo Finance · 1d ago
- ImmunityBio at UBS Global Biopharma Conference 2026: broadening ANKTIVAInvesting.com · 2d ago
- IBRX Stock In Focus As Institutional Investor Boosts Stake By Over 15% In Q3 — All Eyes On ImmunityBio’s London Conferences Next WeekYahoo Finance · 5d ago
- ImmunityBio (IBRX) is Declining For 4 Days Now. What’s Triggering the Selloff?Yahoo Finance · 6d ago
- ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026Yahoo Finance · 8d ago
Who is talking about IBRX stock?
| Newcomers | Regulars | ||
|---|---|---|---|
| IBRX | |||
| IBRX | 12% | 88% | |
| IBRX, 30-day average | |||
| IBRX, 30-day average | 10% | 90% | |
| All stocks | |||
| All stocks | 43% | 57% | |
How does IBRX compare with other Healthcare stocks?
We compare Healthcare stocks by attention, our measure of how much of the conversation each one gets. We add up the likes, replies and reposts on every post about Healthcare stocks on X, Reddit, Stocktwits and YouTube. A stock's attention is its share of that total. Each bar is that share.
| Share of Healthcare attention | ||
|---|---|---|
| IBRX | ||
| IBRX | 2.4% | |
| SLS | ||
| SLS | 33% | |
| CAPR | ||
| CAPR | 8% | |